Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a probable connection between lamotrigine treatment and hair loss, resolving upon discontinuation, suggesting alopecia as a rare side effect of the drug.

This exploratory pilot study reported that using a 2% Oleosome-FGF-2 fusion extract scalp serum twice daily for 84 days in women with telogen effluvium and brittle hair improved hair density, anagen/telogen ratio, hair shaft thickness, and scalp hydration compared to a placebo.

This study found that a proprietary saw palmetto (Serenoa repens) extract significantly increased hair growth and reduced hair shedding in men and women with self-perceived thinning hair over a 90-day period, compared to placebo, without reported adverse events.

This theoretical review analyzes how stress affects hair loss through hormonal and neural pathways, indicating that knowledgeable hairdressers could help in early detection and guide clients toward medical interventions, highlighting a potential collaboration between aesthetic care and medical treatment for stress-induced alopecia.

Most women continued using oral minoxidil for hair loss despite mild to moderate side effects.

This review discusses the mechanisms, causes, and treatment options for telogen effluvium, noting acute cases often resolve by addressing causative factors, while chronic forms remain challenging to treat; recent causes include post-hair transplantation, vitamin D deficiency, and COVID-19.

This study found that three sessions of injectable platelet-rich fibrin (i-PRF+) significantly improved hair follicle density, hair volume, and thickness, as well as patient satisfaction in women with female pattern hair loss, with only minor self-limited adverse effects reported.

In this study, trichoscopy was found to be an effective noninvasive tool for diagnosing female pattern hair loss at early stages, potentially eliminating the need for scalp biopsies.

This study found that trichoscopy is a valuable diagnostic tool for identifying hair loss patterns in women and can help avoid scalp biopsies in unclear cases.

This diagnostic discussion reports that diffuse alopecia areata was identified in a patient with diffuse hair loss, based on specific histopathological features observed in a biopsy.

In a recent study of 15 women with self-perceived hair loss, Viviscal supplementation was associated with an increase in terminal hairs and subjective improvement in hair characteristics.

This article discusses the historic use of oral minoxidil for severe hypertension and the subsequent development of a topical formulation for treating pattern hair loss, but reports no new results.

In this review, researchers explain various hair loss treatments in South Africa, detailing how they work, who can use them, possible side effects, and guidelines for safe application, helping readers make informed decisions about hair care.

This study reviews common hair loss treatments used in South Africa, including minoxidil, topical finasteride, and scalp rollers, detailing their mechanisms, suitable users, side effects, and application needs to help readers make informed choices and create a hair care routine.

This study identified acute localized telogen effluvium as a potential cause of temporal hair loss following rhytidectomy.

This study found that a marine-extract dietary supplement significantly reduced hair shedding and increased hair diameter in premenopausal women with subclinical hair thinning or hair loss after 6 months of use.

This paper proposes an integrated model suggesting that psychological stress, sleep disturbances, nutrition, lifestyle, and various biological factors collectively influence hair health, including hair loss and premature greying.

This study synthesizes evidence on the complex interplay between stress, sleep, nutrition, lifestyle, and systemic health and their impact on hair health, encompassing premature greying, hair loss, and follicle cycling.

In this observational study, patients in India using Sebamed® anti-hair-loss shampoo for 16 weeks experienced improvements in hair growth, thickness, hair fall count, and density, with healthcare professionals reporting good to excellent tolerability in 96.4% of cases.

This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.

This study found that 38% of women with hair loss had a biotin deficiency, suggesting oral biotin supplementation should be based on confirmed biotin deficiency rather than as a general treatment.

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

This article discusses hair shedding in women and does not offer new research results; it highlights the need for objective criteria to define excessive hair shedding.

This article discusses hair loss linked to lithium treatment but reports no new clinical findings.

This study found that mice lacking the type 3 IP(3) receptor in their hair follicles experienced repetitive hair loss and regrowth, indicating disrupted hair-cycle regulation potentially linked to specific signaling pathways.

This article reviews the relationship between hair loss and lithium but does not provide any new clinical findings.

This letter discusses potential hair loss effects of Hedgehog inhibitors but presents no new clinical findings, urging further exploration of this possible class effect.

This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.

This study found that a new formulation kit of Pielus Anti-hair loss lotion and shampoo, used daily for 90 days, was safe and effective in reducing hair loss and increasing hair strength and density among patients with telogen effluvium and/or androgenetic alopecia.

This article is a letter to the editor discussing hair graying and loss potentially induced by imatinib mesylate, but it does not provide new research results.